Episodic Migraine Preventive Treatment | QULIPTA™ (atogepant) HCP

The only once-daily oral preventive CGRP receptor antagonist¹

Turn on quick and continuous migraine preventive power with QULIPTA^™

Across a 12-week clinical trial (QULIPTA 60 mg)^*:

Significant 54% reduction in mean monthly migraine days vs 33% for placebo^1,2

– Similar results were seen in the Phase 2b/3 Dose-finding Study

Quick migraine day reductions were observed Day 1 after the first dose, Week 1, and Month 1³

Over 60% of patients cut their migraine days by at least half vs 29% for placebo¹

^*Data from the Phase 3 ADVANCE trial.

Learn more about THE EFFICACY OF QULIPTA

^*Data from the Phase 3 ADVANCE trial.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily.
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily.
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.

Across a 12-week clinical trial (QULIPTA 60 mg)*:

INDICATION

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

Across a 12-week clinical trial (QULIPTA 60 mg)^*: